[{"id":"713f4f97-d54f-44f6-8d78-99e547a360c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03998345","created_at":"2021-01-18T19:39:17.114Z","updated_at":"2024-07-02T16:36:41.243Z","phase":"","brief_title":"Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A in China","source_id_and_acronym":"NCT03998345","lead_sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 609A"],"overall_status":"Unknown status","enrollment":" Enrollment 24","initiation":"Initiation: 07/25/2020","start_date":" 07/25/2020","primary_txt":" Primary completion: 12/24/2020","primary_completion_date":" 12/24/2020","study_txt":" Completion: 12/30/2020","study_completion_date":" 12/30/2020","last_update_posted":"2020-09-09"}]